ORI-15412 / Origenis - LARVOL DELTA

The novel selective CDK9 Inhibitor ORI-15412 reduces PD-L1 expression and drives the efficacy in combination therapies for melanoma and triple-negative breast cancer (AACR 2025) - "Combined with anti-PD-1 antibody, Vemurafenib, or Trametinib, it enhanced anti-tumor activity, achieving 72-84% TGI in the B16F10 model. These findings highlight ORI-15412 as a pivotal component in combination therapy for hard-to-treat cancers. Its effects on tumor growth inhibition and immune checkpoint modulation support its selection as a clinical candidate for melanoma, TNBC, and other malignancies."

Clinical • Combination therapy • IO biomarker • Breast Cancer • Melanoma • Oncology • Solid Tumor • Triple Negative Breast Cancer • MCL1 • MYC • PD-L1

Mastering metastases by novel selective CDK9 Inhibitor ORI-15412 (AACR 2025) - "The drug was well-tolerated with no observed toxicity, and efficacy was dose-dependent, underscoring its potential for treating metastatic cancers. Having completed all IND-enabling safety and toxicity studies with NOAEL at efficacious doses, ORI-15412 is positioned as a clinical-ready candidate, offering a promising new approach for patients with metastatic cancers, particularly those with brain and bone involvement."

Oncology • MCL1 • MYC